Shares of Biohaven (BHVN 5.04%) are surging on Monday. The company's stock was up about 8% as of midday trading and had climbed as much as 10% earlier in the day. The move comes as the S&P 500 traded mixed and the Nasdaq Composite drifted slightly higher.Shares of the clinical-stage biopharmaceutical company were rising after Biohaven announced a $600 million non-dilutive financing deal with Oberland Capital.A big cash infusionBiohaven revealed it has secured up to $600 million from the investment firm Ober ...

Up to $600 million in non-dilutive capital in exchange for capped milestone and royalty payments on future troriluzole product net sales $250 million to be funded at closing $150 million available at the Company's option upon the achievement of regulatory milestones related to troriluzole Up to $200 million at the mutual agreement of the parties for permitted strategic acquisitions and related costs and expenses NEW HAVEN, Conn., April 28, 2025 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) (Biohaven or the ...

On Friday's news that Biohaven (BHVN -15.34%) withdrew its application for a top investigational drug from an important regulator, investors aggressively traded out of the stock. The clinical-stage biotech was one of the biggest decliners in its industry, exiting Friday with a share price decline of over 15%. This was during a session that was essentially bullish; the S&P 500 index closed 0.6% higher. Strategic withdrawalThat news came not from Biohaven itself, but from the European Medicines Agency (EMA, t ...

LOS ANGELES, April 15, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Biohaven Ltd. ("Biohaven" or "the Company") (NYSE: BHVN) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Biohaven announced its financial results for Q4 and full year 2024 on March 3, 2025. ...

NEW YORK, April 07, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Biohaven Ltd. (“Biohaven” or the “Company”) (NYSE: BHVN).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Biohaven and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On March 3, 2025 ...

Core Insights - Biohaven Ltd. will present 13 abstracts at the 2025 American Academy of Neurology (AAN) Annual Meeting, showcasing its innovative neuroscience pipeline across various development programs [1][2] Company Developments - The presentations include 3 oral and 10 poster presentations, focusing on potential first-in-class therapies for neurological disorders with high unmet needs [2] - Biohaven's pipeline includes Kv7 ion channel modulation, extracellular protein degradation, TRPM3 antagonism, TYK2/JAK1 inhibition, and glutamate modulation [1][6] Oral Presentations - BHV-8000, a selective TYK2/JAK1 inhibitor, shows efficacy in a Parkinson's disease mouse model [3] - BHV-2100, a first-in-class TRPM3 antagonist, demonstrates safety and tolerability for pain and migraine [3] - Novel bispecific degrader BHV-1310 achieves significant IgG reduction in preclinical models [3] Poster Presentations - A qualitative assessment of the epilepsy patient experience through social media [4] - BHV-2100's development for migraine treatment [5] - A modern design for a Phase 2/3 study evaluating BHV-7000 in idiopathic generalized epilepsy [5] Company Overview - Biohaven focuses on discovering and developing treatments in immunology, neuroscience, and oncology, leveraging its drug development experience and proprietary platforms [6]

Shares of early-stage biotech stocks, including Biohaven (BHVN -8.53%), Recursion Pharmaceuticals (RXRX -6.62%), and CRISPR Therapeutics (CRSP -3.22%), plunged in March, with the stocks down 35.3%, 29.6%, and 22.5%, respectively, according to data from S&P Global Market Intelligence .The stocks endured multiple headwinds during the month, especially Biohaven, which had one of its drug candidates deliver underwhelming results in a recent study. In addition, all money-losing biotechs sold off hard along with ...

NEW YORK, March 4, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  Biohaven Ltd ("Biohaven" or the "Company") (NYSE: BHVN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.The investigation concerns whether Biohaven and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On March 3, 2025, Biohaven i ...

Exhibit 99.1 Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2024 Financial Results • Announced acceptance and Priority Review by the United States Food and Drug Administration (FDA) of the new drug application (NDA) for troriluzole in all-genotype spinocerebellar ataxia; expected Prescription Drug User Fee Act (PDUFA) date in 3Q 2025. • Cash, cash equivalents, marketable securities and restricted cash as of December 31, 2024 totaled approximately $489 million. • Reported posi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ____________________________________________________________________________ FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to ______ Commission File Number: 001-41477 Biohaven Ltd. (Exact Name of Registran ...